Legal Opinion of Beijing King & Wood Mallesons Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Beijing Shenzhou Cell Biotechnology Group Co., Ltd.
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Shenzhou Cell
Shenzhou Cell voluntarily disclosed an announcement that its holding subsidiary SCTV04C obtained a notice of approval for drug clinical trials of the recombinant shingles vaccine
Shenzhou Cell voluntarily disclosed an announcement that its holding subsidiary product SCT520FF obtained a notice of approval for drug clinical trials
Agenda for the second extraordinary shareholders' meeting of Shenzhou Cell in 2024
Shenzhou Cell voluntarily disclosed the announcement about the controlling subsidiary company product SCTB41 obtaining the drug clinical trial approval notification.
Notice on the convening of the second interim shareholders' meeting of Shenzhou Cell in 2024
Announcement from Shenzhou Biotech regarding the resignation of a board supervisor and the election of a new board supervisor.
Shenzhou Cell's announcement regarding the resignation of company directors, appointment of new directors, and adjustments to the Audit Committee members.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Shenzhou Cell
Legal Opinion of Beijing King & Wood Mallesons Law Firm on the 2023 Annual General Meeting of Shareholders of Beijing Shenzhou Cell Biotechnology Group Co., Ltd.
Shenzhou Cell 2023 Annual Shareholders' Meeting Meeting Information
Shenzhou Cell 2023 Internal Control Evaluation Report
Shenzhou Cell 2023 Board Audit Committee Performance Report
Report on the audit committee of the board of directors of Shenzhou Cell on the performance of supervisory duties by accounting firms
Shenzhou Cell 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Notice of the 2023 Annual General Meeting of Shareholders of Shenzhou Cell
Shenzhou Cell voluntarily disclosed an announcement that its holding subsidiary product SCTB14 obtained a notice of approval for drug clinical trials
Shenzhou Cell voluntarily disclosed an announcement that its holding subsidiary product SCTB35 obtained a notice of approval for drug clinical trials
Shenzhou Cell voluntarily disclosed the announcement that the holding subsidiary product SCTC21C obtained a notice of approval for drug clinical trials
No Data
No Data